Overview

Huashan Hospital, affiliated with Fudan University, was founded in 1907 and hosts one of China’s National Neurological Disease Medical Centers. Its president is Mao Ying. In June 2025 the Shanghai government named three local BCI companies with in-hospital partnerships at Huashan: Neuracle, NeuroXess and StairMed.

BCI programmes

Neuracle: Huashan was one of three sites, with Xuanwu Hospital and Beijing Tiantan Hospital, in the trial programme behind the NMPA’s March 2026 approval of NEO-ONE SCI. Huashan filed its medical insurance pricing on 28 April 2026, and on 13 July its neurosurgeons performed a commercial implant that Chinese state media described as a world first.

StairMed and CEBSIT: an investigator-initiated trial of the ultra-flexible penetrating implant developed at the Chinese Academy of Sciences’ brain science centre in Shanghai began at Huashan on 25 March 2025. StairMed disclosed 18 cumulative implants on 20 July 2026.

NeuroXess: Huashan is the collaborating site for the Triple-Full registration trial (NCT07720882), which began on 7 July 2026 with an estimated 32 participants and an estimated primary completion date of 30 January 2027. Its design is close to the trial behind Neuracle’s approval.

Why it matters

One hospital now holds an approved implant in paid use, a penetrating-electrode trial and a registration trial for a second hand-function implant. For companies weighing Chinese clinical partners, Huashan is where approval, insurance filing and paid procedures have already run end to end.

Coverage on InsideBCI

• 16 July 2026: China performs first commercial Neuracle NEO implant
• 20 July 2026: StairMed’s penetrating BCI trial at Huashan reaches 18 cumulative implants
• 31 July 2026: Chinese BCI programmes produced four tangible results in July
• 30 September 2026: Chinese Academy of Sciences names brain-computer interfaces a priority field in its 2026 to 2030 plan
• 2 October 2026: NeuroXess participant uses his brain implant to steer AI from sketch to 3D-printed figurine